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Abstract 
Background: Although many thromboembolism risk factors are well defined, formation of throm-
bus or dense spontaneous contrast (sludge) in the left atrium remains enigmatic and confounding. 
Exclusion of the thrombus is extremely important with respect to planned reversal of sinus rhythm. 
Data regarding the routine transesophagal echocardiography (TEE) before cardioversion are incon-
clusive. The authors focused on analyzing the usefulness of TEE before cardioversion by assess-
ment of factors influencing the risk of thrombus and/or dense spontaneous echo contrast with the 
intention of extendingindications for TEE in the group with a high risk of thrombus or to forgo TEE 
in the low risk group. 
Methods: Two hundred sixty-nine consecutive patients with persistent (> 48 h) atrial fibrillation or 
atrial flutter, in whom a direct current cardioversion was planned, were undergoing TEE for the 
detection of the left atrial thrombus or dense spontaneous echocontrast. Additional clinical and 
echocardiographic data were collected. The relationship between both thrombus and dense sponta-
neous echocontrast and covariates was analyzed with the use of binary logistic regression. 
Results: Left atrium (LA) appendage (LAA) thrombus and/or sludge were detected in 79 (29%) 
patients. Signs of dementia in mini mental state examination (hazard ratio: 1.16; p = 0.005), low 
velocities in LAA (hazard ratio [HR]: 3.38; p = 0.032); presence of spontaneous echo contrast in 
LA (HR: 3.38; p = 0,003) consecutive episode of AF (HR: 2.27; p = 0,046); longer duration of atrial 
fibrillation (HR: 1.009; p = 0.022); were significant predictors of thrombus and/or dense spontane-
ous echo contrast. None of the patients with a CHA2DS2VASc score ≤ 1 had thrombus or sludge in 
the LAA. Among patients with a CHA2DS2VASc score > 1, the prevalence of thrombus or sludge in 
LAA was independent of the CHA2DS2VASc score value.  
Conclusions: Amongst many factors, including an established as risk for thromboembolism only a 
few of them increased the risk for the presence of thrombus in LAA: low velocities in LAA, pres-
ence of spontaneous echocontrast, longer duration of arrhythmia, consecutive (not first) arrhythmia 
episode and signs of dementia from a mini-mental state examination questionnaire. It was believed 
that there could be a need for an extension of indications of TEE in vast majority of the patients 
with atrial arrhythmias, due most often to an unpredictable occurrence of thrombus and potentially 
disastrous thromboembolism. The only exception could have been the group of the patients with a 
CHA2DS2VASc score ≤ 1. 
Key words: left atrial appendage thrombus, sludge, atrial fibrillation; atrial flutter; 
cardioversion, transesophagal echocardiography 
 
 
Introduction 
Cerebral stroke and other thromboembolic events caused by thrombus with the source in the 
left atrial appendage (LAA) in patients with atrial fibrillation (AF) and atrial flutter (AFl) might be 
the most serious complications after cardioversion. In subjects with AF, the thrombus in LAA has 
been recognized as a robust independent risk factor for stroke [1–3] and stands as an absolute con-
traindication to cardioversion. The presence of t dense spontaneous echo contrast, commonly called 
sludge, has also been proved to be associated with high embolic risk [4, 5] and all-cause mortality 
[4]. For this reason, thrombus and sludge were recognized as equally dangerous.  
An established way to prevent severe outcomes of cardioversion is the administration of an-
ticoagulants for at least 3 weeks prior to the procedure [6–9].  
Nevertheless, there are many patients diagnosed with presence of thrombus or sludge in the 
LAA despite proper anticoagulation [11, 12]. Transesphageal echocardiography (TEE) has been 
stated as an imaging technique for exclusion or confirmation thrombus and/or dense spontaneous 
echo contrast in the LAA [1, 2, 13, 14]. In the group of patients planned for cardioversion it was 
recommended as a guide, especially in inadequately anticoagulated patients [1, 2, 9, 10]. An unsta-
ble state of patients with inappropriate anticoagulation is also a stated indication for TEE before 
cardioversion in AF or AFl [8, 15]. Except for the above-mentioned clinical conditions, guidelines 
do not commit the present operators to perform TEE routinely before cardioversion, the decision for 
this is usually made on the assumption that the expected risk of thromboembolic complications was 
higher. Therefore, an unresolved issue still remains in question: to do, or not to do TEE routinely 
before cardioversion? 
 Methods 
Two hundred sixty-nine consecutive patients from two medical centers (St. Vincent Hospital 
in Gdynia, Poland and First Department of Cardiology, Medical University of Gdansk, Poland) 
were prospectively enrolled from January 2016 to June 2017. In this group of patients direct current 
cardioversion was planned due to persistent AF or AFl. Exclusion criteria for the study were: ar-
rhythmia shorter than 48 h, contraindications to TEE and lack of consent. All patients included  
underwent transthoracic and TEE.  Ultrasound scanners (GE, Vivid S70, Horten, Norway) equipped 
with a 1.5–4.6 MHz transducer and a 3–8 MHz omniplane phase probe were used. The detailed 
questionnaire regarding state of health was also performed and laboratory blood samples were col-
lected at the day of TEE. The Bioethics      Committee of Medical University of Gdansk approved 
the study.  
In cases which confirm both LAA thrombus and sludge, a decision against reversal of sinus 
rhythm are stated. Further procedures for these patients were made individually, depending on the 
clinical state of the patient and previous treatment. 
Clinical, demographic, echocardiographic and social data were collected: sex, age, body 
mass index (BMI), CHA2DS2VASc score, co-morbidities, mini-mental state examination question-
naire (MMSE), information regarding type and durance of anticoagulation, data of arrhythmia epi-
sode, medical history including smoking, healthcare quality, level of activity and self-reliance; la-
boratory tests including hematology, creatinine, international normalized ratio (INR), activated par-
tial thromboplastin time (aPTT), TTE with automated 2-dimensional measurements of left ventricu-
lar ejection fraction (LVEF), presence or absence of increased filling pressure according the rec-
ommendation of European Association of Cardiovascular Imaging: E/e’ > 11, mitral deceleration 
time < 150 ms, isovolumetric relaxation time < 65 ms, tricuspid regurgitation with Vmax > 2.8 m/s, 
left atrial size measurements. In the TEE there was precise scanning of LAA at angles: 
30/60/90/120 degrees and transgastric 2-chamber 90 degrees with careful adjustment of gain and 
frequency in search of thrombus and dense spontaneous echocontrast (sludge) [6]. The LAA early 
diastolic emptying velocity was also measured. Sludge was defined, as already described in the lit-
erature, as an intracavitary echodensity with viscid gelatinous qualities giving the impression of 
impending precipitation but without a discrete organized mass [17]. There were also other TEE as-
sessments: significant valvular pathology, presence of any spontaneous echo contrast (recognized as 
dynamic, swirling, smoke-like echoes), analysis of LAA velocities and aortic plaque [3]. Both 
transesophageal and transthoracic echocardiography were performed and analyzed by two certified 
echocardiographers (K.K. and M.F.).   
 
Statistical analysis 
Univariate analysis revealed differences between groups of patients with or without throm-
bus or/and dense SEC in LAA and enabled for identification of appropriate covariates for inclusion 
in a binary logistic regression model. Continuous variables like CHA2DS2VASc and MMSE results 
or duration of arrhythmia were analyzed for normality and compared using the Student t test. Eval-
uation of the categorical variables was performed using the χ2 test. Pearson correlation coefficients 
were used to reveal correlations.  
A priori alfa level was 0.05 and values resulting in p < 0.05 were statistically significant. 
A multivariate logistic regression analysis was performed (with the backward likelihood ra-
tio method and p for stepwise removal > 0.10). A p value of less than 0.05 was considered signifi-
cant. Computations were performed using the Statistica version 13.1. 
On the basis of results of the univariate analysis, the following variables were entered into 
the multivariate model: arrhythmia duration, first vs. consecutive episode, left atrium enlargement, 
spontaneous echo contrast, LAA velocities, non-vitamin K oral anticoagulants (NOACs) therapy, 
anticoagulation interruption, MMSE scoring, symptoms of heart failure, mitral stenosis, 
CHA2DS2VASc scoring.  
 
Results 
The clinical and echocardiographic characteristics of patients with and without LAA throm-
bi/sludge are shown in Table 1. Patients with LAA thrombi were more often experienced in AF/AFl 
(not first episode), had longer duration of arrhythmia, larger left atrium, presence of spontaneous 
echo contrast, lower LAA early diastolic emptying velocity, increased left ventricle filling pres-
sures, were treated less often with non-NOACs but more often with vitamin-K antagonists, had de-
clared inappropriate anticoagulation. Analyzing the MMSE score, they more often had a result typi-
cal of dementia, more often had symptoms of heart failure and higher scores in CHA2DS2VASc 
than those without LAA thrombi. 
Thrombus and/or sludge resulting in withdrawal from cardioversion was diagnosed in 79 of 
269 (29%) patients (Fig. 2). 
243 patients of the whole study group (90%) were treated with anticoagulant. The risk of the 
LAA thrombus and/or dense SEC in patients treated with vitamin K antagonist (VKA) (with good 
therapeutic-time-ratio) was higher: 37% patients on VKA therapy had had thrombus vs. 25% in the 
group of patients treated with other anticoagulants; hazard ratio [HR]: 1.62. NOAC therapy in a 
corresponding analysis was superior to other forms of treatment (HR: 0.52), but the result was not 
confirmed in multivariate analysis. CHA2DS2VASc was significantly higher in the group of patients 
with thrombus and/or dense SEC (mean 5 vs. 4) in univariate analysis but surprisingly in multivari-
ate analysis, this factor was not significant. Of note, none of the 16 patients with CHA2DS2VASc 0 
or 1 had thrombus or sludge in LAA (Fig. 1).  
Another startling finding was that thrombus occurred less often in a group of untreated pa-
tients or patients treated for shorter than 3 weeks. Thrombus or/and dense SEC was diagnosed in 8 
(14%) patients from the group of untreated/short-term treated patients versus 50 (26%) among pa-
tients treated adequately but the difference was not clinically significant in both uni- and multivari-
ate analysis. 
Patients with thrombus and/or dense SEC were older but the difference was not significant 
(median 76 vs. 73; p = 0.383). In women, the presence of thrombus and/or dense SEC was also 
more frequent (53% patients with thrombus were female vs. 43% patients without thrombus were 
female), but the difference did not approach statistical significance (p = 0.134). 
Obesity was equally often in both groups of the patients with persistent AF (37% vs. 36%; p 
= 0.918). 
No individual points of the CHA2DS2VASc score revealed statistical difference: diabetes 
and hypertension, previous stroke or thromboembolism, vascular disease and congestive heart fail-
ure were not correlated with higher incidence of thrombus and/or dense SEC.  
Laboratory parameters analyzed (creatinine, hematocrit, platelets, INR, aPTT), were not cor-
related with higher or lower thrombus risk and/or dense SEC.  
In the group of echocardiographic parameters presence of moderate or severe mitral stenosis 
were correlated significantly (3.8% in group with thrombus vs. 0.53% in group without thrombus; p 
= 0.043) but the result was not confirmed in multivariate analysis. Similarly, increased left ventricle 
filling pressures in univariate analysis correlated with higher risk of thrombus (61% in the group of 
thrombus vs. 44% in group without thrombus; p = 0.018), but the factor did not turn out to be an 
independent risk factor in binary regression. None of the other echocardiographic factors, including 
LVEF, significant mitral regurgitation and LAA enlargement were correlated with higher or lower 
risk of LAA thrombus. 
Other clinical features i.e. cancer, smoking, inflammation, recent surgery, kind of arrhyth-
mia (AF vs. AFl) were not correlated with higher risk of thrombus and/or sludge. 
Multivariate analysis revealed only 5 of 53 parameters analyzed as independent risk factors 
for thrombus/dense SEC: low LAA early diastolic emptying velocities (p = 0.032; HR: 3.38; 95% 
confidence interval [CI] 1.11–10.33), presence of spontaneous echocontrast (p = 0.003; HR: 3.38; 
95% CI 1.49–7.67), sequent atrial arrhythmia episode (p = 0.046; HR: 0.44; 95% CI 0.19–0.99), 
low result in mini mental state examination (p = 0.005; HR: 0.86; 95% CI 0.78–0.96) and longer 
duration of arrhythmia (p = 0.022; HR: 1.009; 95% CI 1.01–1.02) (Table 2). 
 Discussion 
The main findings of the present study: 
The prevalence of thrombus or sludge formations in patients with AF and AFl, diagnosed by 
TEE is high (29%) and do not correlate with of CHA2DS2VASc scores when patients CHA2DS2 
score ≤ 1 are excluded — none of the patients with CHA2DS2VASc score ≤ 1 had thrombus or 
sludge in LAA. There is only one independent risk factor for thrombus formation before TEE per-
formance ; cognitive impairment diagnosed in MMSE. There are two other independent risk factors 
; low early diastolic emptying velocities in LAA and the presence of spontaneous echo contrast, and 
were diagnosed during TEE, therefore cannot reveal whether to do or not to do TEE before cardio-
version. 
It was decided to put into the analysis both cases of thrombus and dense spontaneous echo 
contrast (sludge). Differentiation between those two entities is difficult especially before a decision 
of reversal of sinus rhythm [14]. It has been demonstrated that the presence of sludge is strongly 
associated with thrombus, embolic events and poor prognosis [4, 5]. In retrospective analysis of 
Lowe et al. [3] the presence of sludge correlated with similar risk of death but higher risk of throm-
boembolism than thrombus appearance.  
The general incidence of thrombus/sludge in the present study was high. This fact might 
have been caused by prospective nature of the study, especially by a further decision for cardiover-
sion which compelled recognition in uncertain cases as LAA thrombus. Nonetheless, in several sim-
ilar studies the incidence is equal or even higher [3, 19, 20]. 
In this prospective study of 269 consecutive  patients with AF and AFl undergoing TEE, be-
fore attempting cardioversion, many clinical, echocardiographic and social factors were taken into 
account which might have influenced thrombus formation. Among the multiple factors only low 
LAA early diastolic emptying velocities, presence of spontaneous echo contrast, sequent episode of 
AF/AFl, dementia in MMSE, longer episodes of arrhythmia were independent risk factors for 
thrombus formation. Converse to other studies, no significant difference was noted in age, sex, 
LVEF, renal function, lower or higher CHA2DS2VASc score [21, 24], however, in the group with a 
risk score 0 or 1 no thrombi or dense SEC in LAA was diagnosed. In the group scoring higher (two 
or more) there was no statistical difference between the number of points in CHA2DS2VASc score 
and risk of thrombus. 
The present results may underlie creating hypotheses with potential implications for clinical 
decision-making. Regarding contemporary recommendations, in cases of anticoagulation 3 weeks 
prior cardioversion can be performed without the need of any other diagnostic tests. Nevertheless, 
the thrombus or sludge was diagnosed in 25% of patients with declared proper anticoagulation. This 
fact might be a source for beginning a discussion over extending indications for TEE before cardio-
version, similar to the current discussion over necessity of TEE before AF ablation — most ablation 
centers perform TEE routinely despite the general low risk of thrombus/slugde [25, 26]. This pro-
cedure could be supported by important clinical outcomes although the evidence given  in guiding 
this decision is limited [27]. The extension of TEE indications is additionally favored if the results 
of the ACUTE trial take into account, especially lower risk of hemorrhage and higher success rate 
in sinus rhythm reversal in TEE guided patients [7]. Despite the fact, that there are reports on the 
usefulness of other echocardiographic techniques for the prediction of thrombus in LAA, TEE be-
fore cardioversion still remains the gold standard. Kupczynska et al. [28] have demonstrated the 
value of speckle-tracking analysis of the LA wall to identify patients with higher risk of thrombus. 
Additionally, both left ventricle ejection fraction and global longitudinal turned out to be an inde-
pendent risk factor for thrombus and provided additional diagnostic value for discriminating be-
tween patients with and without left atrial thrombus [29].  
One of the most relevant and clinically important findings of the study is the relationship be-
tween cognitive dysfunction and thrombus. Cognitive disorders are very common in patients with 
chronic AF and low anticoagulation compliance  was observed in this group [19]. Those patients 
should be advised that  they would be subjected to TEE before cardioversion independently of a 
declared period of treatment. According to available research this is the first study that suggests 
cognitive disorders as an independent LAA thrombus or sludge risk factor. 
The CHA2DS2VASc score has clinical prediction rules for estimating the risk of stroke in 
patients with non-rheumatic AF associated with thromboembolic stroke. Such a score is used to 
determine whether or not treatment is required with anticoagulation therapy or antiplatelet therapy 
and gives a better stratification of low-risk patients. Indeed, in the present study not a single case of 
thrombus occurred in the group with very low thromboembolic risk (CHA2DS2VASc ≤ 1). The fact 
that reflects the accuracy of CHA2DS2VASc score may help to identify patients in forgoing TEE 
before cardioversion, but these results should be confirmed in larger studies [30]. Additionally, alt-
hough CHA2DS2VASc score correlates directly with annual stroke risk, among patients in this 
study with CHA2DS2VASc > 1 the prevalence of thrombus or sludge in LAA was independent of 
CHA2DS2VASc score values that could suggest additional risk factors of stroke in patients with a 
higher score like atherosclerosis and arterial hypertension. Usefulness of dichotomous scoring of 
CHA2DS2VASc values (≤ 1 and > 1) could simplify clinical every day routine but requires further 
evaluation. 
 
Limitations of the study 
The most important limitation is the uncertain cases that were recognized as suspected 
thrombus and were included in the analysis. In both of the documented centers there was a possibil-
ity to perform differentiation with the use of echocardiographic contrast or computed tomography 
but the decision reached was not to use any of those methods to adjust to clinical conditions in all 
wards performing direct current cardioversion due to the high cost and lack of widespread availabil-
ity for these methods. 
Data regarding anticoagulation were based on questionnaires, with the exception of VKA-
treated patients (INR performed once a week for three weeks before direct current cardioversion). 
Additionally, the focus was not on the important issue of whether and when TEE should be repeated 
to check if the thrombus has been dissolved in anticoagulant therapy. 
Cost-effective analysis goes beyond this study but might be a valuable complement. 
 
Conclusions 
It is believed herein, that there could be a need for an extension of indications to TEE in a vast 
majority of patients with atrial fibrillation and atrial flutter. 
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Table 1. Characteristics of patients with and without left atrial appendage thrombi. 
 Thrombus or 
sludge (+) 
Thrombus or 
sludge (–) 
P 
Clinical 
Age 75.76 ± 8.26 73.01 ± 10.19 0.383 
Female sex  42 (53.16) 82 (43.16) 0.134 
CHA2DS2VASc  5.00 (4.00–6.00) 4.00 (3.00–5.00) 0.071 
CHA2DS2VASc > 
3  
61 (77.22) 138 (72.63) 0.376 
First episode of 
AF/AFl  
24 (30.38) 92 (48.42) 0.013 
AFl  12 (15.19) 41 (21.58) 0.311 
Arrhythmia episode 
duration in weeks  
52.75 ± 106.90 22.53 ± 40.99 0.012 
BMI [kg/m2] 28.97 5.30 29.11 4.94 0.840 
Overweight  33 (41.77) 79 (41.58) 0.939 
Obesity  29 (36.71) 69 (36.32) 0.918 
Arterial hyperten-
sion  
64 (81.01) 147 (77.37) 0.435 
Diabetes  35 (44.30) 68 (35.79) 0.175 
Previous 
stroke/TIA  
17 (21.52) 42 (22.11) 0.939 
Vascular disease 51 (64.56) 100 (52.63) 0.061 
Congestive heart 
failure  
40 (50.63) 72 (37.89) 0.051 
Active cancer  2 (2.53) 7 (3.68) 1.000 
Cancer in medical 
history  
6 (7.59) 16 (8.42) 1.00 
Smoking  5 (6.33) 7 (3.68) 0.520 
Active inflamma-
tion  
6 (7.59) 14 (7.37) 1.000 
Infection in last 3 
months  
16 (20.25) 33 (17.37) 0.729 
Surgery in last 3 
months  
4 (5.06) 12 (6.32) 0.783 
Echocardiography 
LVEF 43.17 ± 12.73 46.24 ± 11.72 0.073 
LA surface  30.02 ± 10.22 27.05 ± 5.22 0.033 
Presence of sponta-
neous echo contrast  
58 (73.42) 62 (32.63) < 0.001 
Low LAA veloci-
ties  
70 (88.61) 113 (59.47) 0.024 
Aortic stenosis 
moderate-to-severe  
4 (5.06) 13 (6.84) 0.785 
Aortic regurgitation 
moderate-to-severe  
2 (2.53) 6 (3.16) 1.000 
Mitral stenosis 
moderate-to-severe  
3 (3.80) 1 (0.53) 0.077 
Mitral regurgitation 
moderate-to-severe  
19 (24.05) 50 (26.32) 0.761 
Aortic prosthesis 4 (5.06) 8 (4.21) 0.752 
Mitral prosthesis 4 (5.06) 5 (2.63) 0.456 
Laboratory 
Creatinine [mg/dL] 0.99 ± 0.38 1.01 ± 0.41 0.479 
Hematocrit [%] 40.49 ± 4.57 40.63 ± 4.68 0.931 
Platelets [G/L] 214.03 ± 55.20 220.07 ± 82.79 0.965 
INR  1.88 ± 0.88 1.73 ± 0.72 0.229 
aPTT ratio  1.35 ± 0.39 1.30 ± 0.33 0.617 
Anticoagulation 
Proper 
anticoagulation 
75 (94.94) 168 (88.42) 0.061 
Anticoagulation 
duration in weeks  
108.96 ± 199.69 123.05 ± 235.11 0.536 
Anticoagulation > 4 
weeks  
67 (84.81) 159 (83.68) 0.819 
NOAC 38 (48.10) 122 (64.21) 0.014 
VKA with TTR > 
85% 
29 (36.71) 43 (22.63) 0.018 
No anticoagulation 
or shorter than 3 
weeks or warfarin 
with TTR < 80% or 
LMWH in prophy-
lactic dose  
8 (14.04) 20 (12.35) 0.818 
Anticoagulation 
interruption in last 
3 months 
12 (15.19) 11 (5.79) 0.028 
Cardiologist-
controlled antico-
agulation 
55/59 (93.22) 126/134 (94.02) 0.830 
Mini mental state examination (MMSE) 
MMSE score 24.67 ± 4.51 26.62 ± 3.38 0.001 
Mild impairment of 
cognitive function 
16 (20.25) 30 (15.79) 0.378 
Dementia 7 (8.86) 2 (1.05) 0.003 
Data are shown as mean ± standard deviation and the number of patients (percentage). AF — atrial fibrillation; atrial 
flutter; LA — left atrium; LAA — left atrium appendage; aPTT — activated partial thromboplastin time; BMI 3 body 
mass index; INR — international normalized ratio; LVEF — left ventricular ejection fraction; NOACs — non-vitamin 
K oral anticoagulants; TIA — transient ischemic attack; VKA — vitamin K antagonists 
 
Table 2. Results of the multivariable analysis: independent predictors of left atrial thrombi. 
 Uni-
variate 
logistic 
regres-
sion 
Multivariate logistic regression 
 p p HR 95% CI 
CHA2DS2VASc 0.049 0.988 1.002 0.74–1.36 
Vascular disease 0.061 0.646 1.213 0.53–2.76 
Mitral stenosis 0.043 0.999 2.65 1.54–4.09 
Spontaneous echo 
contrast 
< 0.001 0.003 3.38 1.49–7.67 
Low LAA veloci-
ties 
< 0.001 0.032 3.38 1.11–10.33 
Increased filling 
pressure 
0.018 0.669 1.19  0.54–2.63 
Congestive heart 
failure 
0.051 0.432 1.39  0.61–3.15 
Dementia in 
MMSE  
<0.001 0.005 0.86 0.78–0.96 
NOAC 0.014 0.381 0.69 0.31–1.58 
Anticoagulation 
interruption 
0.013 0.242 2.13 0.60–7.55 
First arrhythmia 
episode 
0.030 0.046 0.44  0.19–0.99 
Arrhythmia epi-
sode duration 
0.002 0.022 1.009 1.01–1.02 
CI — confidence interval; HR — hazard ratio; LAA — left atrium appendage; MMSE — mini mental state examina-
tion; NOACs — non-vitamin K oral anticoagulants 
 
 
 
 
Figure 1. Percentage of patients with left atrium appendage (LAA) thrombus/sludge by 
CHA2DS2VASc score. 
Figure 2. Examples of the left atrium appendage (LAA) thrombi (A) and LAA sludge (B). 
Figure 3. Percentage of patients with dementia and the presence of left atrium appendage (LAA) 
thrombus/sludge. 
Figure 4. Results of mini-mental state examination questionnaire test and the presence of left atri-
um appendage (LAA) thrombus/sludge. 
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Figure 3 
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